Crinetics appoints former Biogen commercial lead Caren Deardorf to board

Crinetics Pharmaceuticals, Inc.

Caren Deardorf appointed as Class II director, initial term through 2023 annual meeting.
She brings over 20 years at Biogen, led global commercial efforts for Spinraza in SMA.
Board size increased from seven to eight members to accommodate the new appointment.
Deardorf receives annual cash retainer of $40,000 plus $7,500 for committee service; granted 25,000 stock options vesting over 3 years.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Caren Deardorf

Director

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2022-03-11
Filed: March 14, 2022, 7:59 PM ET

the Board approved an increase in its authorized size from seven members to eight members and appointed Caren Deardorf to fill the vacancy created by such increase and serve as a Class II director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Caren Deardorf was appointed as Director at Crinetics Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board approved an increase in its authorized size from seven members to eight members and appointed Caren Deardorf to fill the vacancy created by such increase and serve as a Class II director

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-003510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.